# Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome

> **NCT03004001** · PHASE2 · TERMINATED · sponsor: **Gloria Vega** · enrollment: 3 (actual)

## Conditions studied

- Nephrotic Syndrome

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Alirocumab placebo
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT03004001
- **Lead sponsor:** Gloria Vega
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Difficult recruitment
- **Last updated:** 2022-08-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03004001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03004001, "Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03004001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*